Technologies & Platforms
WuXi Biologics is committed to providing open-access technology platforms so that any company anywhere can efficiently and cost effectively bring new medicines to patients worldwide. Our technology platforms span the entire discovery to manufacturing spectrum.
WuXi Biologics offers five advanced platforms for discovery of antibody-based therapeutics and we leverage these platforms individually or combined to find the ideal therapeutic antibody.
Advanced Hybridoma System
Antibody Drug Conjugates
Our unique Wuxian Express custom protein production platform for generation of R&D-grade proteins and antibodies is designed to fill the gap between transient production and traditional stable pool methodologies. Compared to transient production, Wuxian Express delivers significantly more material, yet only adds 1 week to the overall timeline. Compared to the traditional stable pool production, Wuxian Express is 6 weeks faster and thus offers significant time and cost savings to obtain the same production scale.
Our proprietary CHO K1 cell line development platform was designed to provide high titer production cell lines while also keeping your drug development costs low and to allow ultimate flexibility for cell line use in the production of protein therapeutics.
Cell Culture Development and Manufacturing
WuXi Biologics utilizes three different cell culture technologies that can be used as a standard platform process or customized to meet your protein production requirements.
Fed-batch using single-use disposable bioreactors (up to 2,000 L)
Concentrated Fed-batch approach to deliver higher yields per run
Perfusion cell culture utilizing The ATF™ System technology
Over thirty different cell-based functional/potency assays have been developed for our clients by our 20+ team of bioassay experts. Included are patent pending ADCC and CDC assays.